Telehealth Prescribing Laws in 2026: Navigating Controlled Substance Rules

Why It Matters

The extension preserves patient access to essential controlled‑substance therapies while exposing clinicians to heightened compliance risk from divergent state laws, influencing telehealth business models and multistate practice strategies.

Key Takeaways

• DEA flexibilities for controlled substances expire Dec 31 2026.
• State laws can impose stricter telehealth prescribing rules than federal.
• One in‑person exam required unless a specific federal exception applies.
• Non‑controlled prescriptions follow standard care, no DEA oversight.

Pulse Analysis

The Drug Enforcement Administration’s decision to prolong its COVID‑era telemedicine flexibilities through Dec. 31 2026 keeps the federal in‑person exam waiver for Schedule II‑V drugs alive for another three years. The extension builds on the Ryan Haight Act, which originally required a physical evaluation before a clinician could prescribe controlled substances online. While the DEA has not issued a final rule covering all schedules, the temporary measures allow clinicians to initiate treatment via video visits when a statutory exception—such as care delivered through a DEA‑registered facility—applies. This continuity safeguards access for patients with chronic pain, opioid use disorder, and other conditions that traditionally rely on controlled‑substance therapy.

State boards, however, are not bound by the DEA’s leniency. More than a dozen states have enacted statutes that demand an in‑person assessment, limit telehealth prescribing to established patients, or require periodic face‑to‑face follow‑up for Schedule II drugs. Maryland, for example, obliges providers to assume ongoing responsibility and complete an in‑person exam before any controlled‑substance prescription. When federal and state rules diverge, the stricter standard prevails, forcing clinicians who practice across state lines to maintain a complex matrix of documentation, licensing, and compliance protocols. Failure to honor the most restrictive rule can trigger civil penalties and jeopardize licensure.

For telehealth operators, the pragmatic path is to prioritize non‑controlled prescriptions, where federal oversight is absent and only the standard of care applies. When controlled substances are necessary, providers should implement robust verification workflows, retain video records, and align with each state’s telemedicine statutes. Industry observers expect the DEA to issue a permanent rule before the 2026 deadline, potentially tightening or clarifying the current patchwork. Until then, staying ahead of state legislative changes and investing in compliance technology will be essential to balance patient access with regulatory risk.